AAMU
PGNX

Amundi Asset Management US’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Amundi Asset Management US’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,454
Closed -$12K – 1685
2019
Q3 		$12K Hold
2,454
– – ﹤0.01% 1588
2019
Q2 		$15K Buy
+2,454
New +$11.8K ﹤0.01% 1615

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Amundi Asset Management US's PGNX Position: Q4 2019 in Review

Amundi Asset Management US sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2019, closing a stake of 2,454 shares — an estimated $12K sold.

Amundi Asset Management US first reported a position in PGNX in Q2 2019 and held it in 2 quarters. The position peaked at $15K in Q2 2019. 128 funds tracked by Wall St. Rank hold PGNX as of Q4 2019.

  • Amundi Asset Management US reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2019 after selling out during the quarter.
  • Amundi Asset Management US sold 2,454 Progenics Pharmaceuticals Inc shares in Q4 2019, an estimated $12K.
  • Amundi Asset Management US first reported a position in Progenics Pharmaceuticals Inc in Q2 2019 and held it in 2 quarters.
  • Amundi Asset Management US's Progenics Pharmaceuticals Inc position peaked at $15K in Q2 2019.
  • 128 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2019.

Based on Amundi Asset Management US's 13F filing for Q4 2019, filed 14 Feb 2020.